
Titan Pharmaceuticals’ IND application of Nalmefene Implant nabs FDA’s clearance
Titan Pharmaceuticals has bagged Food and Drug Administration’s (FDA) clearance for its Investigational Drug Administration (IND) application for nalmefene Implant, an opioid antagonist, for a Phase 1 study.